Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.31 |
| ▸ | TTK | P33981 | 2/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778371 | 0.84 | TERT (0.41) | PDE5ACNR2TERTPDE4APDE4B | |
| SCHEMBL3578605 | 0.83 | PDE5A (0.49) | PDE5ATERTPDE4APDE4BPDE4C | |
| SCHEMBL6356420 | 0.80 | PDE5A (0.38) | PDE5AIRAK4NR3C1 | |
| SCHEMBL3579254 | 0.79 | PDE5A (0.46) | PDE5ATERT | |
| SCHEMBL6783770 | 0.77 | TERT (0.38) | PDE5ACNR2TERTPDE4APDE4B | |
| SCHEMBL2402678 | 0.76 | PDE5A (0.53) | PDE5ACNR2 | |
| SCHEMBL3581095 | 0.76 | PDE5A (0.68) | PDE5A | |
| SCHEMBL6356622 | 0.75 | PDE5A (0.46) | PDE5A | |
| SCHEMBL6356946 | 0.75 | PDE5A (0.52) | PDE5ACNR2IRAK4 | |
| SCHEMBL7319688 | 0.75 | PDE5A (0.31) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-6699991-B2 | A ?ONE-POT? PROCESS IS DESCRIBED HEREIN FOR THE PRODUCTION OF PYRAZOLE COMPOUNDS OF GENERAL FORMULA (II) COMPRISING THE STEPS OF REACTING A COMPOUND OF GENERAL FORMULA (III) WITH AN ACYLATING AGENT IN THE PRESENCE OF A BASE AND AN OPTIONAL | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030144530-A1 | Novel process for the preparation of pyrazoles | LAURENCE JAMES HARRIS (GB) | 2003-07-31 | — | — | US | disclosed |
| US-20020173502-A1 | Pharmaceutically active compounds | PFIZER INC | 2002-11-21 | — | — | US | disclosed |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | JAMES HARRIS LAURENCE (GB) | 2002-08-15 | — | — | US | disclosed |
| US-6407259-B1 | REACTING DIETHER COMPOUND WITH ACYLATING AGENT COMPRISING ACID ANHYDRIDE OR ACID HALIDE DERIVATIVE TO FORM PYRAZOLE DERIVATIVE | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | PFIZER INC. | 2002-02-21 | — | — | US | disclosed |
| EP-1176142-A1 | Process for the preparation of pyrazoles | PFIZER INC. (US) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173502-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE3B | PDE5A 1/4885CNR2 1698/4885TERT 4320/4885 |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885CNR2 2454/4885TERT 3231/4885 |
| US-20030144530-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885CNR2 2454/4885TERT 3231/4885 |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885CNR2 2454/4885TERT 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.